Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002377 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
A Phase 3 study of HIV Infections and Cytomegalovirus Retinitis, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 19
- Study locations
NCT00002377 is a Phase 3 study of HIV Infections and Cytomegalovirus Retinitis that has completed, run by Hoffmann-La Roche. The trial reports 19 study locations across 11 states.
The verdict
NCT00002377, a Phase 3 study of HIV Infections and Cytomegalovirus Retinitis, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19
- Study locations
Study Summary
To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.
Conditions Studied
Interventions
- DRUG Valganciclovir
- DRUG Ganciclovir
Study Locations (19)
California
- Univ of California / Irvine - Irvine
- Univ of California / San Diego / Dept of Pediatrics - La Jolla
- Univ of California / San Diego Treatment Ctr - San Diego
- Davies Med Ctr / Institute for HIV Research - San Francisco
- Kaiser Permanente Med Ctr - San Francisco
- QUEST Clinical Research - San Francisco
New York
- New York Univ Med Ctr - New York
- St Luke's - Roosevelt Hosp Ctr / Div of Infect Dis - New York
- New York Hosp - Cornell Med Ctr - New York
Quebec
- Montreal Chest Institute - Montreal
- Royal Victoria Hosp - Montreal
District of Columbia
- Dr Alan Palestine - Washington D.C.
Florida
- Univ of Miami School of Medicine - Miami
Georgia
- Emory Eye Clinic - Atlanta
Massachusetts
- New England Med Ctr - Boston
North Carolina
- Duke Univ Eye Ctr - Durham
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-01 |
| Est. Completion | 2002-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002377
The ClinicalTrials.gov registry entry for NCT00002377 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Valganciclovir is the first listed.
NCT00002377 reports 19 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Quebec.
Frequently Asked Questions
What is clinical trial NCT00002377 about?
NCT00002377 is a clinical study titled "A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes". To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganci...
What is the current status of trial NCT00002377?
This trial is currently completed. It is a Phase 3 study. The study started on 1997-01. Estimated completion is 2002-12.
What conditions does trial NCT00002377 study?
This clinical trial studies the following conditions: HIV Infections, Cytomegalovirus Retinitis.
What interventions are being tested in trial NCT00002377?
The interventions under investigation include: Valganciclovir (DRUG), Ganciclovir (DRUG).
Who is sponsoring clinical trial NCT00002377?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002377 being conducted?
This trial has 19 study locations across California, District of Columbia, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.